Drug intelligence / Profile preview

methylene blue + platelet-rich plasma-fibrin glue

Development stage: Unknown
Lead developer: Mashhad University of Medical Sciences
Modality: Small Molecules
Administration: Oral, Topical

Overview

This combination therapy consists of oral methylene blue and platelet-rich plasma-fibrin glue (PRP-FG) dressing. It is being investigated for the treatment of non-healing diabetic foot ulcers (DFU). The treatment works by improving hypoxic conditions in wound areas caused by diabetes using methylene blue, while the PRP-FG component provides growth factors that stimulate cell growth, differentiation, and wound healing. The PRP-FG is applied as a dressing to the wound, while methylene blue is administered orally dissolved in milk.

Other names: MB + PRP-FG

Targets

Fibrin polymerization interface

Beyond the preview

Go deeper on methylene blue + platelet-rich plasma-fibrin glue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylene blue + platelet-rich plasma-fibrin glue.

Explore the full profile